整合酶抑制剂在HIV感染全程管理中的应用优势  

Application advantage of integrase inhibitors in full processing strategy during HIV infection

作　　者：汪笛 栗翠林 肖静 曾永秦 逄晓莉 孔雅娴[1] 赵红心[1,2] WANG Di;LI Cui-lin;XIAO Jing;ZENG Yong-qin;PANG Xiao-li;KONG Ya-xian;ZHAO Hong-xin(First Department of Infectious Diseases,Beijing Ditan Hospital,Capital Medical University,100015,China)

机构地区：[1]首都医科大学附属北京地坛医院感染一科,100015 [2]北京大学地坛医院教学医院感染一科,100015

出　　处：《传染病信息》2019年第6期567-573,共7页Infectious Disease Information

基　　金：国家自然科学基金(81672000);“十三五”国家科技重大专项(2018ZX10715-005);北京市医管中心项目(DFL20191802)。

摘　　要：随着HIV抗反转录病毒治疗(antiretroviral therapy, ART)的研究进展,ART时机的不断提前以及ART药物的迅速发展,HIV感染者可以获得期望寿命。现在对HIV感染者的关注不仅仅在于AIDS本身,更多应该关注HIV感染者的合并症,甚至心理疾病。中华医学会发布的《艾滋病诊疗指南(2018版)》提出全程管理的概念,而整合酶抑制剂在HIV感染全程管理的多个环节中优势显著,本文就其在全程管理中的地位以及应用展开讨论。Life expectancy has been available to HIV patients following the progress of antiretroviral therapy(ART)research,advance of ART timing and development of ART drugs.Nowadays,in addition to AIDS itself,more attention should be paid to the complications and even psychological diseases of HIV patients.In the Chinese Medical Association Guidelines for Diagnosis and Treatment of AIDS in 2018,the concept of full processing management was proposed,and integrase inhibitors show a significant benefit in multiple aspects of full processing management for HIV infection.This article discusses the status and application of integrase inhibitors for the full processing management of HIV infection.

关 键 词：HIV 整合酶抑制剂 全程管理 

分 类 号：R512.91[医药卫生—内科学]